Neuromodulation market opportunity
According to Boston Scientific’s (BSX) estimates, the market opportunity for its neuromodulation portfolio grew ~14% YoY (year-over-year) in 2017 to ~$2.5 billion. The company expects the market to grow at a compound annual rate of 10%–15% between 2017 and 2020.
Boston Scientific’s neuromodulation portfolio aims to offer personalized therapy to more than 25 million chronic neuropathic pain patients, 2 million stroke patients, and 10 million patients with neurodegenerative disorders. The company is leveraging its SCS (spinal cord stimulation) MultiWave platform, DBS (deep brain stimulation) franchise, broad research pipeline, and international expansion strategy to advance its position in the underpenetrated neuromodulation space.
Spinal cord stimulation portfolio
Boston Scientific deploys Illumina’s 3D neural-targeting algorithm and different implantable pulse generators to stimulate spinal cord target points according to patients’ needs. The company expects Infinion CX leads coupled with Illumina 3D’s algorithm to offer better outcomes for pain patients.
Boston Scientific’s acquisition of Cosman Medical, announced in July 2016, has added radiofrequency ablation technology to its portfolio. This technology is used as an early-stage therapy for chronic pain patients and is generally used before patients progress to SCS options. In the next article, we’ll discuss Boston Scientific’s SCS portfolio’s growth prospects in greater detail.